venetoclax + ixazomib + dexamethasone

This combination therapy, evaluated in a Phase I/II clinical trial (NCT03399539) led by the Mayo Clinic, consists of venetoclax, ixazomib citrate, and dexamethasone for the treatment of relapsed multiple myeloma. Venetoclax is a selective small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein often overexpressed in myeloma cells, which helps restore the natural process of apoptosis. Ixazomib is an oral proteasome inhibitor that targets the 20S proteasome, disrupting protein homeostasis and inducing cellular stress leading to cell death. Dexamethasone is a synthetic corticosteroid that provides synergistic anti-tumor activity and manages treatment-related inflammation. The regimen aims to overcome therapeutic resistance in relapsed patients by simultaneously targeting apoptotic pathways and the protein degradation machinery.

Other names

Venetoclax, Ixazomib, and DexamethasoneVenetoclax + Ixazomib + Dexamethasone